Opexa Therapeutics, Inc. (NASDAQ: OPXA) is a biotechnology company developing personalized immunotherapies with the potential to treat major illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases, such as neuromyelitisoptica (NMO). These therapies are based on Opexa’s proprietary T-cell technology. The company’s leading therapy candidate, Tcelna, is a personalized T-cell immunotherapy that is in a phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive MS. For more information, visit the company’s website atwww.opexatherapeutics.com.